Transplantation of neural progenitor cells into the human CNS
- PMID: 36182630
- DOI: 10.1016/j.molmed.2022.09.009
Transplantation of neural progenitor cells into the human CNS
Abstract
The development of regenerative medicine for spinal cord injury (SCI) and intractable diseases of the nervous system using neural progenitor cells (NPCs) has shown great promise, and several clinical trials have begun. In addition, ex vivo gene therapy using genetically engineered NPCs was recently initiated in the clinical setting by Baloh et al., putatively showing enhanced therapeutic effects. Thus, the era of next-generation NPC transplantation therapy is beginning to dawn.
Keywords: ALS; GDNF; chemogenetics; engineered neural progenitor cells; ex vivo gene therapy; spinal cord injury (SCI).
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests H.O. is a founder scientist of SanBio Co. Ltd. and K Pharma Inc.
Comment on
-
Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.Nat Med. 2022 Sep;28(9):1813-1822. doi: 10.1038/s41591-022-01956-3. Epub 2022 Sep 5. Nat Med. 2022. PMID: 36064599 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
